ClinicalTrials.gg
CompletedNCT02758613Updated Dec 7, 2017Results posted

A Study of Baricitinib (LY3009104) in Healthy Chinese Participants

A Phase 1 interventional study of Baricitinib and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The main purpose of this study is to investigate the safety and tolerability of the study drug known as baricitinib in healthy Chinese participants. The study will measure how the body absorbs, breaks down and gets rid of baricitinib. The study will last about 20 days, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy Chinese males agreed to use methods of or are Chinese females, as determined by medical history and physical examination
  • Have a of 19.0 to 24.0 kilograms per meter squared (kg/m²), inclusive, at screening.
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not by the investigator.
  • Have given written approved by Lilly and the ethical review board (ERB) governing the site.

Exclusion criteria

Exclusion Criteria:

  • Have a history of adverse drug reactions or "drug allergy" to more than 3 types of systemically administered medications.
  • Have an abnormality in the 12-lead (ECG).
  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
  • Have a history of stomach or intestinal surgery.
  • Current or recent history (\<30 days prior to screening of a bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection.
  • Have an (ANC) less than 2000 cell/microliter (μL) (2 x 109/liter [L]).
  • Have current herpes zoster or simplex within 90 days prior to the first dose,
  • Have evidence of active or latent tuberculosis (TB)
  • Have used or intend to use over-the-counter, prescription medication, or Chinese herbal preparation within 14 days prior to dosing and during the study.
  • Have consumed grapefruit, grapefruit juice, or grapefruit products within 7 days prior to the first dose or are unwilling to abide by the grapefruit restrictions during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    2 milligram (mg) Baricitinib

    2mg Baricitinib administered orally, once on Day 1 and once a day (QD) on Days 4 through 10 (7 days).

    Drug: Baricitinib

  • Experimental
    4mg Baricitinib

    4mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).

    Drug: Baricitinib

  • Experimental
    10mg Baricitinib

    10mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).

    Drug: Baricitinib

  • Placebo comparator
    Placebo

    Placebo matching Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).

    Drug: Placebo

Interventions

  • Administered orally.

    Also known as: LY3009104

  • DrugPlacebo

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Clinically Significant Event(s)

    Clinically significant events were defined as a moderate to severe adverse event, abnormal clinical sign, or clinical laboratory finding that may pose risk to the well-being of the participant. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.

    Time frame: Baseline through Study Completion (up to Day 20)

Secondary outcomes

  1. Pharmacokinetics(PK): Maximum Concentration (Cmax) of Baricitinib

    Maximum observed drug concentration for single dose and Cmax as steady date for multiple dosing.

    Time frame: Day 1: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Postdose; Day 5: Predose; Day 6: Predose; Day 7: Predose; Day 8: Predose; Day 9: Predose; Day 10: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Postdose

  2. Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Baricitinib

    Area under the concentration versus time curve from zero to infinity (AUC0-inf) during single dose and area under the concentration versus time curve (AUCtau,ss) during multiple dose of baricitinib at steady state.

    Time frame: Day 1: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Postdose; Day 5: Predose; Day 6: Predose; Day 7: Predose; Day 8: Predose; Day 9: Predose; Day 10: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Postdose

07

Results

Posted Dec 7, 2017

Participant flow

Treatment
Participant flow — Treatment
MilestonePlacebo2mg Baricitinib4mg Baricitinib10mg Baricitinib
Started8898
Received at least one dose of study drug8898
Completed6888
Not completed2010
Withdrew: Physician and sponsor decision1000
Withdrew: Withdrawal by subject1010
Follow-up
Participant flow — Follow-up
MilestonePlacebo2mg Baricitinib4mg Baricitinib10mg Baricitinib
Started6888
Completed6888
Not completed0000

Outcome measures

PrimaryNumber of Participants With One or More Clinically Significant Event(s)

Clinically significant events were defined as a moderate to severe adverse event, abnormal clinical sign, or clinical laboratory finding that may pose risk to the well-being of the participant. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.

Time frame:
Baseline through Study Completion (up to Day 20)
Reported as:
Count of participants · Participants
Number of Participants With One or More Clinically Significant Event(s)
ParticipantsPlacebo2mg Baricitinib4mg Baricitinib10mg Baricitinib
Number of Participants With One or More Clinically Significant Event(s)4024
SecondaryPharmacokinetics(PK): Maximum Concentration (Cmax) of Baricitinib

Maximum observed drug concentration for single dose and Cmax as steady date for multiple dosing.

Time frame:
Day 1: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Postdose; Day 5: Predose; Day 6: Predose; Day 7: Predose; Day 8: Predose; Day 9: Predose; Day 10: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Postdose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics(PK): Maximum Concentration (Cmax) of Baricitinib
nanogram per milliliter (ng/mL)2mg Baricitinib4mg Baricitinib10mg Baricitinib
Single Dose Day 124.3 ± 1747.8 ± 42147 ± 28
Multiple Dose Day 1028.0 ± 2448.0 ± 28136 ± 17
SecondaryPharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Baricitinib

Area under the concentration versus time curve from zero to infinity (AUC0-inf) during single dose and area under the concentration versus time curve (AUCtau,ss) during multiple dose of baricitinib at steady state.

Time frame:
Day 1: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Postdose; Day 5: Predose; Day 6: Predose; Day 7: Predose; Day 8: Predose; Day 9: Predose; Day 10: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Postdose
Reported as:
Geometric mean · nanogram * hour per milliliter (ng*h/mL)
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Baricitinib
nanogram * hour per milliliter (ng*h/mL)2mg Baricitinib4mg Baricitinib10mg Baricitinib
Single Dose Day 1139 ± 12270 ± 17777 ± 9
Multiple Dose Day 10145 ± 12265 ± 18771 ± 14

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/8 (0%)4/8 (50%)
2mg Baricitinib—0/8 (0%)1/8 (12.5%)
4mg Baricitinib—0/9 (0%)2/9 (22.2%)
10mg Baricitinib—0/8 (0%)4/8 (50%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlacebo2mg Baricitinib4mg Baricitinib10mg Baricitinib
Alanine aminotransferase increasedInvestigations1/80/81/92/8
Electrocardiogram abnormalInvestigations2/80/80/90/8
Aspartate aminotransferase increasedInvestigations1/80/81/91/8
Blood bilirubin increasedInvestigations0/80/80/91/8
Blood creatine phosphokinase increasedInvestigations0/81/80/90/8
Blood triglycerides increasedInvestigations0/80/80/91/8
Blood uric acid increasedInvestigations0/81/80/90/8
Protein urine presentInvestigations1/80/80/90/8
HypotensionVascular disorders1/80/80/90/8
Orthostatic hypotensionVascular disorders0/80/80/91/8

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo2mg Baricitinib4mg Baricitinib10mg BaricitinibTotal
Mean26.6 ± 5.430.8 ± 7.326.6 ± 3.527.6 ± 6.727.8 ± 5.8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo2mg Baricitinib4mg Baricitinib10mg BaricitinibTotal
Female00000
Male889833
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo2mg Baricitinib4mg Baricitinib10mg BaricitinibTotal
American Indian or Alaska Native00000
Asian889833
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Placebo2mg Baricitinib4mg Baricitinib10mg BaricitinibTotal
China889833
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Placebo2mg Baricitinib4mg Baricitinib10mg BaricitinibTotal
Mean22.34 ± 1.2122.15 ± 1.7521.87 ± 1.2821.68 ± 1.3922.01 ± 1.38
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Beijing, 100034, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2016
First posted
May 2, 2016
Start
May 2016
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Results first posted
Dec 7, 2017
Last update
Dec 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02758613
Responsible party
Sponsor
First posted
May 2, 2016
Start date
May 2016
Primary completion
Jul 2016
Completion
Jul 2016
Results posted
Dec 7, 2017
Last update
Dec 7, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion